Devises / EXAS
EXAS: Exact Sciences Corporation
46.80
USD
0.82
(1.72%)
Le taux de change de EXAS a changé de -1.72% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 46.63 et à un maximum de 47.72.
Suivez la dynamique Exact Sciences Corporation. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
EXAS Nouvelles
- Zacks Perrigo to Report Q2 Earnings: What's in Store for the Stock?
- Zacks Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Zacks Charles River Q2 Earnings Preview: What's in Store for the Stock?
- Zacks Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
- Zacks Tempus AI Taps Growing ICI Market With New xM Assay
- Zacks Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
- Zacks Henry Schein to Report Q2 Earnings: What's in Store for the Stock?
- Zacks KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
- Zacks CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
- Zacks Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
- Zacks HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
- Seeking Alpha Baron Discovery Fund Q2 2025 Commentary (BDFIX)
- Zacks Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
- Zacks Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
- Zacks Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
- Zacks Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Seeking Alpha Baron Health Care Fund Q2 2025 Shareholder Letter
- Zacks Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
- Zacks How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
- Investing Canaccord Genuity reiterates Buy rating on Exact Sciences stock ahead of study
- Zacks Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
- Zacks Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet
- Zacks Tempus AI Raises 2025 Financial Outlook: What's Backing It?
- Investing Exact Sciences to release Q2 2025 results on August 6
Range quotidien
46.63
47.72
Range Annuel
39.97
72.83
- Clôture Précédente
- 47.54
- Ouverture
- 47.62
- Bid
- 46.80
- Ask
- 47.10
- Plus Bas
- 46.63
- Plus Haut
- 47.72
- Volume
- 4.880 K
- Changement quotidien
- -1.72%
- Changement Mensuel
- -11.45%
- Changement à 6 Mois
- -14.14%
- Changement Annuel
- -15.05%
31 juillet, jeudi
11:30
USD
- Act
- Fcst
- Prev
- 47.999 K
11:30
USD
- Act
- Fcst
- -68.3%
- Prev
- -1.6%
12:30
USD
- Act
- Fcst
- 0.4%
- Prev
- 0.2%
12:30
USD
- Act
- Fcst
- 2.6%
- Prev
- 2.7%
12:30
USD
- Act
- Fcst
- 0.2%
- Prev
- 0.1%
12:30
USD
- Act
- Fcst
- 2.3%
- Prev
- 2.3%
12:30
USD
- Act
- Fcst
- 0.2%
- Prev
- -0.1%
12:30
USD
- Act
- Fcst
- 0.7%
- Prev
- -0.4%
12:30
USD
- Act
- Fcst
- 0.0%
- Prev
- -0.3%
12:30
USD
- Act
- Fcst
- 0.9%
- Prev
- 0.9%
12:30
USD
- Act
- Fcst
- 1.0%
- Prev
- 1.2%
12:30
USD
- Act
- Fcst
- 0.7%
- Prev
- 0.8%
12:30
USD
- Act
- Fcst
- 224 K
- Prev
- 217 K
12:30
USD
- Act
- Fcst
- 1.966 M
- Prev
- 1.955 M
12:30
USD
- Act
- Fcst
- 222.299 K
- Prev
- 224.500 K
13:45
USD
- Act
- Fcst
- 42.4
- Prev
- 40.4
14:00
USD
- Act
- Fcst
- 2.3%
- Prev
- 2.0%
14:30
USD
- Act
- Fcst
- 2 B
- Prev
- 23 B
15:30
USD
- Act
- Fcst
- Prev
- 4.245%
15:30
USD
- Act
- Fcst
- Prev
- 4.265%